Kaken Pharmaceutical Co., Ltd.

TSE:4521.T

3901 (JPY) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 72,04472,98476,03474,97989,23494,16798,432101,991109,21893,89588,94987,04787,99486,43385,02682,92779,94476,41475,52574,923
Cost of Revenue 33,82233,42834,45834,07338,75340,36642,40544,53947,58044,76045,16944,96144,92844,06944,12043,14041,24639,22038,49237,752
Gross Profit 38,22239,55641,57640,90650,48153,80156,02757,45261,63849,13543,78042,08643,06642,36440,90639,78738,69837,19437,03337,171
Gross Profit Ratio 0.5310.5420.5470.5460.5660.5710.5690.5630.5640.5230.4920.4830.4890.490.4810.480.4840.4870.490.496
Reseach & Development Expenses 12,54315,7898,4206,7366,41810,2618,1526,4505,8837,6157,0456,3026,5926,8537,8737,6966,8086,5336,0456,271
General & Administrative Expenses 3100000000001,6702,0331,8981,8352,7052,7831,8111,9461,920
Selling & Marketing Expenses 16,13400000000001,4691,7071,7791,7242,1352,4852,6142,5942,763
SG&A 16,16515,47615,83316,15517,32018,72420,17420,02020,30420,58920,5913,1393,7403,6773,5594,8405,2684,4254,5404,683
Other Expenses 573341306911085924747-426-506-445-317-407-397-243-390-352-435-424
Operating Expenses 28,70831,55324,50823,11523,96629,20528,52726,74126,48628,50227,90527,46923,97724,13825,36425,28224,81324,76224,34024,863
Operating Income 9,5147,99817,06417,78826,51224,59227,49630,70735,14620,63115,87214,61119,08918,22615,54214,50513,88512,43212,69312,308
Operating Income Ratio 0.1320.110.2240.2370.2970.2610.2790.3010.3220.220.1780.1680.2170.2110.1830.1750.1740.1630.1680.164
Total Other Income Expenses Net 282-1,183-3,18086980330186381140-2,022-379-439-4,523-4,681-4,613-5,151-5,282-4,649-5,366-6,227
Income Before Tax 9,7966,81713,88518,65726,59224,92227,68631,09235,29218,61115,49614,17814,56613,54510,9299,3548,6037,7837,3276,081
Income Before Tax Ratio 0.1360.0930.1830.2490.2980.2650.2810.3050.3230.1980.1740.1630.1660.1570.1290.1130.1080.1020.0970.081
Income Tax Expense 1,7701,3774,3365,2527,2227,1478,6439,07514,1486,4885,7615,1866,2835,3324,1943,7743,4973,1803,4412,664
Net Income 8,0255,4409,54913,40519,37017,77519,04322,01721,14312,1229,7358,9918,2828,2136,7345,5795,1064,6023,8863,417
Net Income Ratio 0.1110.0750.1260.1790.2170.1890.1930.2160.1940.1290.1090.1030.0940.0950.0790.0670.0640.060.0510.046
EPS 212.66144.79251.44347.37494.89445.78470.55536.7510.54290.9228.28206.6184.92175.74137.58111.2296.784.8480.4673.08
EPS Diluted 212.66144.79251.44347.37494.89445.78470.55536.7510.54290.9228.28206.6184.92175.74137.58111.2296.2281.6666.4856.98
EBITDA 12,26711,33820,04520,55729,27527,14029,99432,93937,63422,82118,10216,92521,20220,32117,58416,70815,81414,08313,81813,032
EBITDA Ratio 0.170.1550.2640.2740.3280.2880.3050.3230.3450.2430.2040.1940.2410.2350.2070.2010.1980.1840.1830.174